title: Timing effects of uracil-induced urolithiasis on amplification of second-stage promotion in rat bladder carcinogenesis.
abstract: The post-initiation enhancing activities of the non-genotoxic agent NaHCO3 and the genotoxic agent N-ethyl-N-(4-hydroxybutyl)nitrosamine (EHBN) in combination with uracil-induced urolithiasis were investigated in a rat bladder carcinogenesis model. Animals were treated with 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) for 4 weeks, and then 3% uracil was given for 3 weeks in the early (weeks 4-7), middle (weeks 8-11) or late (weeks 12-15) post-initiation phase. In addition, administration of 3% NaHCO3, 20 ppm EHBN or no chemical supplement was performed for the 13 weeks when the rats were not receiving BBN or uracil. NaHCO3 in sequential combination with early and middle stages uracil treatment strongly enhanced tumorigenesis in the urinary bladder, while EHBN treatment amplified lesion development at the middle stage only of uracil treatment. DNA synthesis and associated epithelial surface alterations observed by scanning electron microscopy tended to be increased in the NaHCO3 and EHBN groups without BBN initiation, independently of uracil treatment timing. The present results demonstrated that uracil-induced urolithiasis during the middle post-initiation phase is highly active in enhancing bladder tumor development under the influence of a promoter or carcinogen.
authors.affiliation: First Department of Pathology, Nagoya City University Medical School.
authors.forename: M A
authors.initials: MA
authors.lastname: Shibata
authors.forename: R
authors.initials: R
authors.lastname: Hasegawa
authors.forename: M
authors.initials: M
authors.lastname: Sano
authors.forename: T
authors.initials: T
authors.lastname: Shirai
authors.forename: S
authors.initials: S
authors.lastname: Fukushima
mesh_terms: D000818:Animals; D001639:Bicarbonates / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D002085:Butylhydroxybutylnitrosamine / Q000031:analogs & derivatives / Q000494:pharmacology; D002273:Carcinogens / Q000008:administration & dosage; D004334:Drug Administration Schedule; D008297:Male; D051381:Rats; D011916:Rats, Inbred F344; D012964:Sodium / Q000494:pharmacology; D017693:Sodium Bicarbonate; D014498:Uracil / Q000008:administration & dosage*; D001743:Urinary Bladder / Q000033:anatomy & histology; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced* / Q000473:pathology; D014545:Urinary Calculi / Q000139:chemically induced
chemical_list: D001639:Bicarbonates; D002273:Carcinogens; D002085:Butylhydroxybutylnitrosamine; C010723:N-ethyl-N-(4-hydroxybutyl)nitrosamine; D014498:Uracil; D017693:Sodium Bicarbonate; D012964:Sodium